Fp889long Term Follow Up of Active Management Versus Minimization of Immunosuppressives of Bk Virus Associated Nephropathy After a Kidney Transplant

Halim, Medhat A; Al-Otaibi, Torki; Gheith, Osama; Mosaad, Ahmed; Zakaria, Zakaria; Said, Tarek; Nair, Prasad; Nampoory, M.R.N.

doi:10.1093/ndt/gfv185.78

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients of group I suffered from increased serum creatinine, and lowering of creatinine clearance and of hemoglobin levels than group II patients. These findings were in agreement with Abdel Halim et al , who assessed basal graft function by measurement of glomerular filtration rate; they found its reduction to 35.4 ± 18.8 mL/min/1.73 m 2 at 1 year.…”

Section: Discussionsupporting

confidence: 92%

“…In our study, all BKPyV‐positive cases showed positive decoy cells in urine preparations, with mean value of 4.27 ± 1.79 cell/10 hpf, thus making them an important simple, cheap, and non‐invasive screening diagnostic modality for clinical assessment of risk. Our BKPyV viral load mean and median values for urine and blood samples estimated by Q‐PCR were 2,259,004.54 ± 5,929,031.55 and 10,342.14 ± 7181.12 copies/mL, respectively, median 9000 and 5000 copies/mL, respectively; this was in accordance with Abdel Halim et al , who stated that BK viremia was considered significantly positive when it exceeded 10,000 copies/mL. Furthermore, Drachenberg et al found that significant BKPyV replication (plasma DNA PCR load >10,000 copies/mL), with or without kidney dysfunction, defines presumptive BK nephropathy.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Prevalence of polyoma BK virus infection among living‐donor renal transplant recipients

Ansary

Elhamid

Saadi

et al. 2016

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 89%

Prevalence of polyoma BK virus infection among living‐donor renal transplant recipients

Ansary

Elhamid

Saadi

et al. 2016

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…However, some authors have also reported no additional benefit with BKPyV viral clearance following the use of leflunomide. 185 The rates of graft loss and acute rejection associated with leflunomide were highly variable, with estimates varying up to 20%. 98,174 Other complications associated with leflunomide include gastrointestinal disorders (diarrhea, nausea) and hematologic toxicity (bone marrow suppression, hemolysis, thrombotic microangiopathy) while prolonged use is reportedly associated with fungal pneumonia, neuropathic pain and rhabdomyolysis.…”

Section: Management Of Bkpyv Infectionmentioning

confidence: 99%

Polyoma BK Virus in Kidney Transplant Recipients: Screening, Monitoring, and Management

et al. 2021

View full text Add to dashboard Cite

Polyomavirus BK virus (BKPyV) infection is an important complication of kidney transplantation and allograft failure. The prevalence of viremia is 10%-15%, compared with BK-associated nephropathy (BKPyVAN) at 3%-5%. Given that there are no effective antiviral prophylaxis or treatment strategies for BKPyVAN, active screening to detect BKPyV viremia is recommended, particularly during the early posttransplant period. Immunosuppression reduction to allow viral clearance may avoid progression to severe and irreversible allograft damage. The frequency and duration of screening are highly variable between transplant centers because the evidence is reliant largely on observational data. While the primary treatment goals center on achieving viral clearance through immunosuppression reduction, prevention of subsequent acute rejection, premature graft loss, and return to dialysis remain as major challenges. Treatment strategies for BKPyV infection should be individualized to the recipient's underlying immunological risk and severity of the allograft infection. Efficacy data for adjuvant therapies including intravenous immunoglobulin and cidofovir are sparse. Future well-powered and high-quality randomized controlled trials are needed to inform evidence-based clinical practice for the management of BKPy infection.

show abstract

A systematic review of the various treatment options regarding the effectiveness of IVIG for nephropathy due to BK virus

Nikoeenejad,

Einollahi,

Ebrahimi

2021

RJMM

View full text Add to dashboard Cite

"Abstract: Introduction: BK virus is an opportunistic infectious disease that causes disease and serious problems when the immune system is suppressed. One of the treatments used against this virus is intravenous immunoglobulin (IVIG). We aimed to review the major relevant articles in case of the efficacy of IVIG and determine its usefulness. Methods: We searched online databases such as PubMed, MEDLINE, Wiley, EMBASE, ProQuest Dissertations and Thesis, ISI Web of Knowledge, Scopus, and Google scholar. Two reviewers have independently assessed and extracted the titles and abstracts. Disagreements were being fixed by discussion. Where resolve was not feasible, a third review author was discussed. Results: We screened a total of 6 full texts. Three studies evaluated the effectiveness of IVIG in the Treatment of BK Infection in Renal Transplant Patients. Also, three studies assessed the various treatment options for Nephropathy due to the BK virus. Results showed that mean peak BK reduced with IVIG therapy after a one-year follow-up. Also, a high percentage of patients have functioning grafts after IVIG therapy. Conclusion: A review of studies shown powerful follow-up and early decrease of immunosuppression leading detection of BK viremia, with qualitative monitoring, can avoid the progress of clinically notable BK nephropathy. Combination treatment IVIG is more successful in removing viral load in patients with BKVAN, compared with traditional standard-ofcare therapy. Keywords: BK virus, nephropathy, treatment"

show abstract

Fp889long Term Follow Up of Active Management Versus Minimization of Immunosuppressives of Bk Virus Associated Nephropathy After a Kidney Transplant

Cited by 3 publications

References 0 publications

Prevalence of polyoma BK virus infection among living‐donor renal transplant recipients

Prevalence of polyoma BK virus infection among living‐donor renal transplant recipients

Polyoma BK Virus in Kidney Transplant Recipients: Screening, Monitoring, and Management

A systematic review of the various treatment options regarding the effectiveness of IVIG for nephropathy due to BK virus

Contact Info

Product

Resources

About